

How do I take Teglutik®?

Teglutik® comes in a 300 ml bottle along with a reusable 10 ml syringe to help with accurate dosing.

You should take Teglutik® as advised by your doctor or pharmacist.


Turn the bottle the right way up and remove the syringe. **You can now administer Teglutik® into the centre of the mouth, on the middle of the tongue** (see figure 4). Be sure to administer the whole content of the syringe

1



Gently shake the bottle by turning it 180° for at least 30 seconds

4



Teglutik® works best when it is placed into the centre of the mouth, on the middle of the tongue, because it gives you the best control over swallowing the medicine

2



Take the syringe, remove the tip and insert the syringe into the adaptor opening on the bottle

5



Wash the syringe with water only and store Teglutik® safely

3



Turn the bottle upside down and pull the plunger down to fill the syringe with Teglutik®. Stop when the plunger reaches the 10 ml mark

For detailed instructions on how to administer Teglutik®, please refer to the Patient Information Leaflet found in the Teglutik® packaging.



NEW
TEGLUTIK®
riluzole 5mg/ml
oral suspension



Your treatment for amyotrophic lateral sclerosis (ALS)

You have been prescribed Teglutik® to treat amyotrophic lateral sclerosis (ALS) because it can help to slow the progression of the disease. Please read this information carefully before you start taking the medicine to make sure that you get the most from your treatment.

MARTINDALE PHARMA®
Making lives better

What is Teglutik®?

Teglutik® is a medicine used to treat ALS, a disease that affects the nervous system and causes muscles to waste away. It is sometimes also called motor neuron disease (MND) because ALS is the most common type of MND.

What does Teglutik® do?

Teglutik® contains an ingredient called riluzole that helps to slow down the progression of the disease, possibly by stopping nerves from being damaged. Because of this, riluzole can help you to remain in the milder stages of the disease for longer, when taken correctly.

Teglutik® has a nectar-like texture, much like double cream, that is easy for you to swallow so you can continue to take your medication for as long as possible.

What side effects might I get?

The most common side effects (affecting more than 1 in 10 patients) are:



Tiredness



Feeling sick



Increased blood levels of some enzymes of the liver (transaminases)

Please read the Patient Information Leaflet in the Teglutik® package for the full list of potential side effects for this medicine. If you experience any side effects, talk to your doctor, nurse or pharmacist. This includes any side effects that are not listed. You can also help by reporting side effects directly via the Government Scheme at: www.mhra.gov.uk/yellowcard. By reporting side effects, you can help provide more information on the safety of this medicine.

DO NOT take Teglutik® if:



you are allergic to riluzole or any of the ingredients of this medicine (you can find these on the package)



you have liver disease



you are pregnant or breast-feeding

Please also talk to your doctor before taking Teglutik® if:

- your skin or the whites of your eyes are yellow (jaundice); you are itching all over, feeling sick or being sick
- your kidneys are not working well
- you have any fever
- you are less than 18 years old

Where can I find out more about ALS and Teglutik®?

If you have any specific questions about your health or ALS treatment, you should speak to your doctor or MND nurse.

YOUR MND NURSE IS:

WHO CAN BE CONTACTED ON:

TREATMENT START DATE:

The MND Association is a national charity in England, Wales and Northern Ireland who provide information and support for patients, families and carers. This includes advice on living with MND, including real stories from other patients and families, and answers to some questions you may have.

You can visit their website at: <http://www.mndassociation.org/>



MARTINDALE PHARMA
Making lives better

Adapted from: Teglutik® Patient Information Leaflet.
Available at: <https://www.medicines.org.uk/emc/PIL.31216.latest.pdf>
Last accessed: March 2016.

CRIT/03/2016/450 Date of preparation: March 2016